WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , 

ISSN 2457-0400

Impact Factor  :  6.711

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR April 2024 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

  • WJAHR: APRIL ISSUE PUBLISHED

    APRIL 2024 Issue has been successfully launched on 1 APRIL 2024.

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

  Indexing

  • Google Scholar
  • Index Copernicus
  • SOCOLAR, China
  • Research Bible, Fuchu, Tokyo. JAPAN
  • Cosmos Impact Factor
  • Scientific Indexing Services (SIS)
  • UDLedge Science Citation Index
  • International Impact Factor Services
  • International Society for Research Activity (ISRA) Journal Impact Factor (JIF)
  • IFSIJ Measure of Journal Quality
  • Scientific Journal Impact Factor (SJIF)
  • International Scientific Indexing, UAE (ISI) (Under Process)
  • International Impact Factor Services (IIFS)
  • Web of Science Group (Under Process)
  • Directory of Research Journals Indexing
  • Scholar Article Journal Index (SAJI)
  • International Scientific Indexing ( ISI )
  • Academia
  • Scope Database

Abstract

OFF LABEL USE OF DIRECT ORAL ANTICOAGULANTS (DOACS) COMPARED TO VITAMIN K ANTAGONIST (VKA) FOR LEFT VENTRICULAR THROMBUS (LVT): A SYSTEMATIC REVIEW AND META-ANALYSIS

Abdulkareem AlGarni, Abdulmajeed Aljuhiman and Dr. Ayman F. Soliman*

ABSTRACT

Background: Left ventricular (LV) thrombus is associated with high burden of stroke, systemic embolization and mortality. Direct oral anticoagulants (DOACs) has emerged as an alternative treatment to Vitamin K Antagonist (VKA). In absence of randomized controlled trials, we aim to conduct systematic review and meta- analysis for the available observational studies. Objective: to evaluate effectiveness and safety of DOACs Versus VKA in Setting of LV thrombus. Methods: We searched Ovid Medline, Embase, PubMed, Google scholar and ClinicalTrials.gov for comparative Observational studies of DOACs Versus VKA in LV thrombus treatment. Results: We found 9 eligible observational studies including 2160 patients reported as 4 published studies and 5 abstracts without full report. Meta-analysis showed no difference between two interventions in terms of stroke and systemic embolization (SSE) RR= 1.09, 95% CI (0.90 –1.31), thrombus resolution RR= 1.01, 95% CI (0.62-1.63) and Major bleeding events RR =1.06, 95% CI (0.66-1.71). Conclusion: There is no difference between DOACs and VKA in terms of effectiveness and safety for treatment of LV thrombus. Randomized controlled trial is needed to evaluate DOACs in the treatment of LV thrombus.

[Full Text Article] [Download Certificate]